
AbbVie Inc. company profile
$295.03+0.20%Close 13 Nov 2026 · Market value $524.5B
About AbbVie Inc.
AbbVie Inc. is a global, research-based biopharmaceutical company that operates as a single business segment engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. Its portfolio spans immunology, neuroscience, oncology and aesthetics, with products including Skyrizi, Rinvoq, Humira, Vraylar, Botox Therapeutic, Imbruvica, Venclexta, Botox Cosmetic and Juvederm Collection. The company sells primarily to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies and independent retailers, and also to managed care providers, hospitals and physicians. Its products are sold worldwide, with a significant U.S. presence and sales in markets across North America, the European Union, Japan and other regions.
A summary of the business section of the company's latest annual report, filed 20 Feb 2026.
Company facts
| Ticker | ABBV · NYSE |
|---|
| Sector | Pharmaceuticals |
|---|
| Industry | Biotechnology |
|---|
| Index | S&P 500 |
|---|
| Fiscal year ends | 31 December |
|---|
| Reporting currency | USD |
|---|
| CIK | 1551152 |
|---|
| Latest annual report | 10-K, filed 20 Feb 2026 |
|---|
Officers and directors
| Name | Role | Shares owned | Latest Form 4 |
|---|
| A. Saleki-Gerhardt | EVP, CHIEF OPERATIONS OFFICER | 204K | Shares withheld for tax, 27 Feb 2026 |
|---|
| R. Michael | CHAIRMAN OF THE BOARD AND CEO · Director | 179K | Shares withheld for tax, 27 Feb 2026 |
|---|
| T. Freyman | Director | 135K | Grant or award, 8 May 2026 |
|---|
| R. Thakkar | EVP, R&D and CSO | 55.4K | Shares withheld for tax, 27 Feb 2026 |
|---|
| S. Reents | EVP, CHIEF FINANCIAL OFFICER | 38.8K | Shares withheld for tax, 27 Feb 2026 |
|---|
| R. Austin | Director | 38.5K | Grant or award, 8 May 2026 |
|---|
| R. Alpern | Director | 35.6K | Grant or award, 9 May 2025 |
|---|
| F. Waddell | Director | 29.0K | Grant or award, 8 May 2026 |
|---|
| W. Burnside | Director | 27.0K | Grant or award, 8 May 2026 |
|---|
| M. Meyer | Director | 16.5K | Grant or award, 8 May 2026 |
|---|
| R. Roberts | Director | 13.7K | Grant or award, 8 May 2026 |
|---|
| J. Davis | Director | 2.5K | Grant or award, 8 May 2026 |
|---|
| S. Quaggin | Director | 2.5K | Grant or award, 8 May 2026 |
|---|
| Stewart Jeffrey Ryan | EVP, CHIEF COMMERCIAL OFFICER | — | Gift, 12 Nov 2026 |
|---|
| Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER | — | Option exercise, 14 Aug 2026 |
|---|
| Hart Brett J | Director | — | Grant or award, 8 May 2026 |
|---|
| FALK THOMAS J | Director | — | Grant or award, 8 May 2026 |
|---|
| RAPP EDWARD J | Director | — | Grant or award, 8 May 2026 |
|---|
| Purdue David Ryan | SVP, Controller | — | Open-market sale, 4 Mar 2026 |
|---|
| Siatis Perry C | EVP, GC AND SECRETARY | — | Sale under a 10b5-1 plan, 2 Mar 2026 |
|---|
Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.
ABBV in the terminal
The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.